New blueprint for respiratory health chartered to benefit Healthy China

Professor Guo Yanfei from Beijing Hospital stated that COPD treatment has now formally entered a new era of biologic therapy.

Professor Wen Fuqiang from West China Hospital of Sichuan University emphasized that early intervention and precision therapy are fundamental to achieving optimal quality of life and favorable long-term outcomes for patients.

He highlighted that breakthroughs in disease mechanism research and the emergence of novel targeted therapies have reshaped the approach to disease management.

"With the widespread application of biologics, the field has now entered a new era of precision medicine," he said, expressing his confidence that these advances would benefit broader patient populations in the near future.

The summit served as a significant platform for fostering collaboration and exchange in the field of respiratory immunology, both in China and internationally, helping improve the quality and standardization of care for asthma and COPD in China, and expanding precision targeted treatment for type 2 inflammatory airway diseases.

As a global leader in healthcare, Tong said, Sanofi remains committed to developing innovative therapies that provide patients with improved treatment options, upholding its mission to "Chase the Miracles of Science to Improve People's Lives", and contributing to the ambitious vision of "Healthy China 2030".

Please contact the writer at hanjingyan@chinadaily.com.cn